Navigation Links
Hadasit Bio-Holdings CEO Letter to Shareholders
Date:4/9/2013

l Industrial Research and Development (BIRD) Foundation to support BioMarCare's partnership with Ariadne Inc. (based in Florida).
  • The Israeli Office of the Chief Scientist (OCS) in the Ministry of Industry, Trade and Labor provided our companies with substantial grants totaling over $3M.
  • Over 5M NIS were raised from the public through a rights-offering with an outstanding participation of over 99% of eligible rights holders. Several leading Israeli institutional investors participated.
  • Hadasit Bio-Holdings Ltd. was one of the first Israeli biotech companies to establish an American Depositary Receipts (ADR) program exposing the TASE stock in a liquid and transparent manner to the American market. We are now 'Blue Sky' approved in over 30 states and the ADR holders have purchased over 2.5% of the outstanding TASE shares.
  • Thrombotech Ltd. was acquired by D-Pharm and we now hold ~14% of the publicly traded company.
  • Future Plans:

    Over the year we saw a substantial increase in the global interest in the growth potential of the Israeli biotechnology industry, and more specifically, an increase concerning HBL. We believe this growing interest in our Company was generated due to our unique model of a holding company that maintains a strong affinity for and involvement with a leading and innovative private hospital. In the coming year, we intend to take advantage of this interest by forging ties and building strategic partnerships with leading pharmaceutical entities, manufacturers and investors.

    With the ongoing maturation of the current portfolio companies, investment options in new and attractive companies are always being examined. In order to manage risk in the best possible way and thoroughly utilize the relative advantage HBL has as a holding company with a hospital in its 'back yard', we have developed an innovative business model for these potential investments. The model i
    '/>"/>

    SOURCE Hadasit Bio-Holdings Ltd.
    Copyright©2012 PR Newswire.
    All rights reserved

    Page: 1 2 3 4 5 6

    Related biology technology :

    1. Hadasit Bio-Holdings Ltd. Reports Significant External Financing for Portfolio Companies
    2. KAHR Medical, a Hadasit Bio-Holdings Portfolio Company, to Raise $2.6 Million
    3. Hadasit Bio-Holdings Interviewed by Wall Street Reporter
    4. Hadasit Bio-Holdings Ltd. Portfolio Companies - ProtAb Ltd. and KAHR Medical Ltd. to Receive NIS 10.7 Million (Over $2.8 Million USD) in Additional Government Grants
    5. NeoStems CEO Letter to Shareholders
    6. Genesis Biopharma Issues Letter To Shareholders
    7. Bacterin Receives Letter From NYSE MKT LLC Regarding Timely Notice of Record Date for 2012 Annual Meeting of Stockholders
    8. Elsevier to Participate in SCOAP3 With the Journals Physics Letters B and Nuclear Physics B
    9. Ronald L. Chez Files Amended 13D and Letter to the Board
    10. Mangrove Partners Sends Letter to Stockholders of Nabi Biopharmaceuticals
    11. Amarantus BioSciences Issues CEO Letter to Shareholders
    Post Your Comments:
    *Name:
    *Comment:
    *Email:
    (Date:12/17/2014)... IN (PRWEB) December 17, 2014 ... Laboratory Excellence following its most recent COLA inspection. ... by COLA, a national healthcare accreditation organization. Accreditation ... standards of quality in day-to-day operations, demonstrate continued ... pass a rigorous on-site laboratory survey. ...
    (Date:12/17/2014)... , Dec. 17, 2014  United Therapeutics Corporation ... executive promotions as well as changes to Martine ... Executive Promotions United Therapeutics announced the ... and Co-Chief Executive Officer and David Zaccardelli , ... In connection with these promotions, Dr. Rothblatt,s title will ...
    (Date:12/15/2014)... METTLER TOLEDO is pleased to announce that ... with PVM technology , is now available. The ... tool continuously captures high-resolution images under a wide ... prepares a report pairing the most relevant images ... This compelling blend of high resolution images and ...
    (Date:12/15/2014)... BEIJING , Dec. 15, 2014  Origin Agritech Limited ... "), a technology-focused supplier of crop seeds in ... results for its fiscal year 2014 ended September 30, 2014, ... The Company will host a teleconference on January 8, ... Beijing time to discuss the results. To participate ...
    Breaking Biology Technology:Xeno Diagnostics Receives 3rd Award for Laboratory Excellence 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 2United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 3United Therapeutics Corporation Announces Executive Promotions and CEO Compensation Change 4New Real-Time In Situ Probe-Based Video Microscope from METTLER TOLEDO 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 2Origin Agritech Limited to Announce Fiscal 2014 Annual Financial Results on January 8th, 2015 3
    ... 18 Martek Biosciences,(Nasdaq: MATK ) announced today ... patented, vegetarian form of DHA omega-3 for brain, eye,and ... vegetarian DHA,Oroweat 9 Grain Bread with life,sDHA from Bimbo ... Pacific Northwest, California, Arizona,and Nevada., "This new launch ...
    ... Baxter,International Inc. (NYSE: BAX ) announced today ... an additional $2 billion of the company,s,common stock to ... authorization., Baxter has less than $700 million of ... that was authorized in March,2007. Shares will be repurchased ...
    ... Calif., March 18 TorreyPines Therapeutics,Inc. (Nasdaq: ... Phase II study of,NGX267, a muscarinic agonist in ... syndrome., The company is conducting a randomized, ... to evaluate,the safety, tolerability and efficacy of this ...
    Cached Biology Technology:Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 2Martek Announces Launch of Oroweat 9 Grain Bread, First Bread with Martek's life'sDHA 3Baxter's Board of Directors Approves New Share Repurchase Authorization of $2 Billion 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 2TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 3TorreyPines Therapeutics Initiates Phase II Study of Muscarinic Agonist NGX267 for Treatment of Xerostomia 4
    (Date:11/21/2014)... Wash. , Nov. 20, 2014 C-Labs ... for the Internet of Things (IoT), today announced the ... of chief operating officer. Previously a strategic advisor to ... finance, and operations. Mr. Traynor is based out of ... . He reports to Chris Muench , Chief ...
    (Date:11/18/2014)... NEW YORK , Nov. 18, 2014 /PRNewswire/ ... iris-based identity authentication solutions, and MorphoTrust USA ... solutions and services, today announced a strategic partnership ... across enterprise, motor vehicle administration (MVA), airport screening ... leader in identity-related solutions, MorphoTrust serves consumers through ...
    (Date:11/7/2014)... led by Dr. Debra Auguste, associate professor, biomedical ... The City College of New York, have identified ... for one of the most aggressive forms of ... have a high mortality rate owing to aggressive ... therapeutic options. However, Professor Auguste,s team, discovered the ...
    Breaking Biology News(10 mins):C-Labs Names Former Microsoft and Bsquare Executive as Chief Operating Officer 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 2EyeLock, MorphoTrust Form Strategic Partnership to Pursue Commercial Enterprise Deployments 3
    ... training video produced by Rafael Ortega, MD, the vice-chair ... Boston Medical Center (BMC) and professor of anesthesiology at ... is featured in this week,s New England Journal ... is the fifth BMC-produced video to appear in the ...
    ... After 30 years with Chip Supply, Inc., President ... Perrott served in various capacities through the ... tenure, Chip Supply grew into the largest independent die ... global provider of high reliability interconnect solutions, serving the ...
    ... BUFFALO, NY -- Exposure to air pollution early in life ... may alter her DNA and may be associated with premenopausal ... Buffalo have shown. The findings indicated that higher air ... increase levels of E-cadherin, a protein important to the adhesion ...
    Cached Biology News:Pulse oximetry training video by BMC anesthesiologist published in NEJM 2Air pollution exposure affects chances of developing premenopausal breast cancer 2